Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prostate Cancer
100%
Chemoprevention Trial
100%
Selenium
100%
Selenium Supplementation
50%
Disease Progression
45%
Cancer Prevention
40%
Cancer Clinical Trials
40%
Nutritional Prevention
40%
Watchful Waiting
35%
Prostate-specific Antigen
33%
Treatment Effect
33%
Standard of Care
28%
Prostate Cancer Risk
23%
Essential Trace Elements
16%
Safety Endpoints
16%
Selenium Pollution
16%
Serum Markers
16%
Hormone Therapy
16%
Placebo Groups
16%
Placebo
16%
Prostate Cancer Progression
16%
Liver Enzymes
16%
Metastatic Disease
16%
Kidney Enzymes
16%
Enzyme Level
16%
Mild Symptoms
16%
Treatment Lag
16%
Double-blind Trial
16%
Randomized Double-blind
14%
PSA Velocity
14%
Biomarker Expression
7%
Alternative Agents
7%
Blood Biomarkers
7%
Baseline Biopsy
7%
Treatment Morbidity
7%
Recurrent Disease
7%
Life-limiting Conditions
7%
Treatment Planning
7%
Control Phase
7%
Biopsy Specimen
7%
Placebo-controlled
7%
Complete Data
7%
Effect Magnitude
7%
Treatment Options
7%
Protein Profile
7%
Ethical Considerations
7%
Disease Pattern
7%
Disease Risk
7%
Biospecimens
7%
Tissue Biomarkers
7%
Risk Reduction
7%
Clinical Trials
7%
Blood Samples
7%
Clinical Interventions
7%
Determinants of Disease
7%
Absence of Data
7%
Natural Progression
7%
Predictive Value
7%
Accruals
7%
Intervention Studies
7%
Serum Proteins
7%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Selenium
100%
Diseases
33%
Placebo
30%
Malignant Neoplasm
30%
Disease Exacerbation
29%
Prostate Specific Antigen
25%
Cancer Incidence
18%
Liver Enzyme
12%
Trace Element
12%
Cancer Growth
12%
Kidney Enzyme
12%
Endocrine Therapy
12%
Biological Marker
11%
Recurrent Disease
5%
Clinical Trial
5%
Intervention Trial
5%
Plasma Protein
5%
Morbidity
5%
Medicine and Dentistry
Prostate Cancer
50%
Chemoprophylaxis
50%
Selenium
50%
Supplementation
44%
Diseases
33%
Watchful Waiting
27%
Disease Exacerbation
16%
Biological Marker
11%
Blood Proteins
5%
Cancer Incidence
5%
Biopsy Technique
5%
Morbidity
5%
Clinical Trial
5%
Clinical Intervention
5%
Malignant Neoplasm
5%
Recurrent Disease
5%
Treatment Option
5%
Placebo
5%
Oral
5%
Treatment Planning
5%
Arm
5%
Intervention Trial
5%